Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
768.810.18%
QQQ
720.180.17%
BTC/USD
78407.460.8634%
DIA
530.400.69%
GLD
403.200.88%
TLT
82.340.16%

Eikon Therapeutics Inc

EIKNNASDAQ
Trade with Public
Trade with Public
$10.86
-0.10-0.91%
At close: Sep 3, 5:00 PM EST
$10.86
-0.10-0.91%
Pre-Market: 7:00 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Eikon Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eikon Therapeutics (EIKN).

Price Target Range — 3 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Sell
Consensus RatingOverweight# Analysts6Avg. Consensus PT$25Upside to Avg. PT+130.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026WedbushRobert DriscollPT CutUnderperform$5→$4
May 12, 2026WedbushRobert DriscollPT CutUnderperform$7→$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $5 to $4.
Benzinga Newsdesk

PRO
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.
Benzinga Newsdesk

PRO
Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target

Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and maintains $7 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Eikon Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating.
Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Eikon Therapeutics with Overweight Rating, Announces Price Target of $29

JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overweight rating and announces Price Target of $29.
Benzinga Newsdesk

This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Wall Street analysts changed outlook on top names. For all changes, upgrades, downgrades and initiations, see analyst ratings page.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved